Table 4 Allele and genotype frequencies of TNF-α -308G/A, -238G/A, -376G/A and +489G/A SNPs according to outcome in the study group
From: Evaluation of TNF-α genetic polymorphisms as predictors for sepsis susceptibility and progression
Survivors n (%) 60 (42.9%) | Deceased n (%) 103 (57.1%) | Total n (%) 163 | P value; OR (95% CI) | |
|---|---|---|---|---|
TNF-α -308G/A | ||||
AA | 1 (1.7%) | 1 (1.0%) | 2 (1.2%) | 0.88; 1.90 (0.11–31.26) |
AG | 16 (26.7%) | 20 (19.4%) | 36 (22.1%) | 0.32; 1.52 (0.71–3.24) |
GG | 43 (71.7%) | 82 (79.6%) | 125 (76.7%) | Reference |
AA+AG | 17 (28.3%) | 21 (20.4%) | 38 (23.3%) | 0.25; 1.54 (0.73–3.23) |
TNF-α -238G/A | ||||
AG | 3 (5.0%) | 3 (4.9%) | 8 (4.9%) | 0.67; 1.71 (0.33–8.80) |
GG | 57 (95.0%) | 98 (95.1%) | 155 (95.1%) | Reference |
TNF-α -376G/A | ||||
AG | 0 (0.0%) | 4 (3.9%) | 4 (2.5%) | 0.29; 0.18 (0.009–3.45) |
GG | 60 (100.0%) | 99 (96.1%) | 159 (97.5%) | Reference |
TNF-α +489 G/A | ||||
AA | 2 (3.3%) | 1 (1.0%) | 3 (1.8%) | 0.56; 3.15 (0.27–35.84) |
AG | 13 (21.7%) | 31 (30.1%) | 44 (27%) | 0.35; 0.66 (0.31–1.39) |
GG | 45 (75.0%) | 71 (68.9%) | 116 (71.2%) | Reference |
AA+AG | 15 (25.0%) | 32 (31.1%) | 47 (28.8%) | 0.47; 0.74 (0.36–1.51) |